Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Akkermansia muciniphila for asymptomatic hyperuricemia
ChiCTR2500100894Phase 4Recruiting
- Sponsor
- Jingdezhen Second People's Hospital
- Start
- Apr 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of akkermansia muciniphila in hyperuricemia (3 arms), sponsored by Jingdezhen Second People's Hospital. Primary endpoints: Biochemical function and Composition of gut microbiota. Started Apr 2025; status: recruiting.
02
Drugs
akkermansia muciniphila
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on ChiCTR2500100894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100894.